Patients with gout flare have increased odds of cardiovascular events, independent of traditional cardiovascular risk factors.
Gout flares seem to be associated with a transient increase in the risk for cardiovascular events.
Researchers used dual-energy computed-tomography to assess the prevalence of monosodium urate deposition in the spines of patients with gout.
Researchers examined the associated changes in serum urate levels with health-related quality of life in patients with gout.
For relatively young and healthy patients with gout caused by renal underexcretion of uric acid, low-dose benzbromarone (LDBen) has a greater urate-lowering effect than low-dose febuxostat.
Researchers investigated the association between gout and dementia in older adult patients.
Researchers investigated the impact of time to remission, number of flares, and time on immunosuppressives after remission on estimated glomerular filtration rate in patients with lupus nephritis.
Researchers investigated whether a gout stigma exists among rheumatologists and how it influences their perceptions of patients and treatment decisions.
Researchers investigated the safety and efficacy of oral methotrexate as co-therapy with pegloticase for sustained urate-lowering response.
In-hospital mortality rate lower for patients with acute heart failure exacerbation who received colchicine for gout flare.